▲关注药财社聚焦医药界▲本文约3000字,阅读时长约10分钟2026年FDA审批序幕拉开。康方生物研发的双抗Ivonescimab正式向FDA递交上市申请,叩响全球市场大门。此外,礼来、默沙东、武田等企业的潜在重磅药物有望在今年获美国FDA批准上市。1月12日,Summit公司宣布,已正式向美国FDA递交Ivonescimab(依沃西单抗)联合化疗的生物制品许可申请(BLA)。此举不仅为这款来自...
Source Link▲关注药财社聚焦医药界▲本文约3000字,阅读时长约10分钟2026年FDA审批序幕拉开。康方生物研发的双抗Ivonescimab正式向FDA递交上市申请,叩响全球市场大门。此外,礼来、默沙东、武田等企业的潜在重磅药物有望在今年获美国FDA批准上市。1月12日,Summit公司宣布,已正式向美国FDA递交Ivonescimab(依沃西单抗)联合化疗的生物制品许可申请(BLA)。此举不仅为这款来自...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.